Fig. 6.
Inhibition of SLC1A5 activity suppresses mesothelioma tumor growth. A/B Meso-1 cells, grown as spheroids, were injected (3 million cells/site) into each front flank in NSG mice (5 mice/group). When tumors were first detected, at 7 weeks, treatment was initiated three times/week with 0 or 15 mg/Kg V-9302 (SLC1A5 inhibitor). Tumor size was monitored weekly and at 10 weeks the tumors were harvested and imaged, and total tumor lysate was prepared to detect expression of the indicated markers. C/D Wild-type and SLC1A5 knockout (Meso1-SLC1A5-KOc1-1-1) Meso-1 cells, grown as spheroids, were injected into each front flank (3 million cells/site) in NSG mice (5 mice/group). Tumor size was measured weekly and at 12 weeks the tumors were harvested and imaged, and total cell lysate was prepared to detect expression of the indicated markers. Values are mean ± SEM and asterisks indicate a significant reduction as compared to control, n = 10 tumors, p < 0.05. E Schematic describing the impact of glutamine restriction on human mesothelioma cells and tumors. The model is described in the Discussion.